Q-omics provides the consensus-scored UBQLN3 profile across patient tissues and cancer cell-line models. UBQLN3 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, UBQLN3 is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, UBQLN3 RNA expression shows 12,766 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight DLBC, BRCA, and LSCC as cancer lineages where UBQLN3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBQLN3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBQLN3 survival associations across molecular data types. UBQLN3 RNA expression shows survival associations in the most cancer types (8), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBQLN3 RNA expression–survival associations across cancer types. High UBQLN3 expression shows unfavorable associations in DLBC, LUAD, SCLC, STAD, GBM and THCA. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify DLBC as the clearest survival context for UBQLN3 RNA expression.
This table summarizes UBQLN3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for UBQLN3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBQLN3 shows lower tumor expression in LUSC and KIRC and higher tumor expression in BRCA, THCA and LIHC. The BRCA box plot shows higher UBQLN3 RNA expression in tumor versus normal tissue (log2 FC = +0.007, t-test p = .042).
This table shows molecular features associated with UBQLN3 in patient tissues and cancer cell lines. In patient samples, UBQLN3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, UBQLN3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
